Insmed (INSM) Other Non Operating Income (2013 - 2026)
Insmed (INSM) posted Other Non Operating Income of -$531000.0 for Q2 2026, up 27.85% on a QoQ basis from -$736000.0 in Q1 2026, and down 217.22% year-over-year from $453000.0 in Q2 2025.
Analysis
Insmed (INSM) Other Non Operating Income (2013 - 2026) Analysis & Trends
Insmed has reported Other Non Operating Income for 14 years, with the latest figure at -$531000.0 in Q2 2026.
- On a quarterly basis, Other Non Operating Income fell 217.22% year-over-year to -$531000.0 in Q2 2026; TTM through Jun 2026 was -$3.7 million, a 54.07% decrease from a year earlier, with the FY2025 full-year figure at -$1.8 million, down 680.08% from the prior year.
- Other Non Operating Income was -$531000.0 for Q2 2026 at Insmed, up from -$736000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $3.5 million in Q4 2023, with the low at -$4.3 million in Q2 2022.
- Average Other Non Operating Income over 5 years is -$412611.1, with a median of -$567000.0 recorded in 2025.
- The sharpest annual moves came in 2022 and 2024: Other Non Operating Income plunged 2804.65% in 2022, then surged 254.08% in 2024.
- Over 5 years, Other Non Operating Income stood at $1.1 million in 2022, then soared by 210.27% to $3.5 million in 2023, then slumped by 75.19% to $870000.0 in 2024, then slumped by 309.54% to -$1.8 million in 2025, then soared by 70.87% to -$531000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$531000.0 (Q2 2026), -$736000.0 (Q1 2026), and -$1.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -531,000.00 |
| Mar 31, 2026 | -736,000.00 |
| Dec 31, 2025 | -1.82 Mn |
| Sep 30, 2025 | -603,000.00 |
| Jun 30, 2025 | 453,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Dec 31, 2024 | 870,000.00 |
| Sep 30, 2024 | -3.85 Mn |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 2.36 Mn |
| Dec 31, 2023 | 3.51 Mn |
| Sep 30, 2023 | -1.30 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | -1.53 Mn |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | -1.51 Mn |
| Jun 30, 2022 | -4.31 Mn |
| Mar 31, 2022 | -1.25 Mn |
| Sep 30, 2021 | -476,000.00 |
| Jun 30, 2021 | -17.69 Mn |